Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Latest full-year results from official filings.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
Feb 2026: Big Health raised $23.7m in strategic funding co-led by .406 Ventures and AlleyCorp. No adverse media involving Big Health found in HSH's search of the last 24 months.
Data breaches, cyber incidents, regulator action and assurance status.
No data breaches, cyber incidents or regulator action involving Big Health found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Recalls, safety notices, regulator action and clinical safety concerns.
Digital therapeutics (SleepioRx, DaylightRx) are FDA-cleared; no recalls, safety notices or warning letters involving Big Health found in HSH's search of the last 24 months.
Contract delivery, go-lives, terminations and disputes.
May 2025: trade press reported Sleepio still lacked NHS England national funding despite 2022 NICE guidance, limiting access in England (Scotland offers it). Feb 2026: company cited Henry Ford and Northwell as US delivery partners.